The expression of melanoma-associated antigen A (MAGE-A) in oral squamous cell carcinoma: an evaluation of the significance for tumor prognosis

Trippel, Anna; Halling, Frank; Heymann, Paul; Ayna, Mustafa; Al‐Nawas, Bilal; Ziebart, Thomas

doi:10.1007/s10006-019-00778-x

Cited by 6 publications

(4 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MAGE-A mRNA was expressed in different degrees in peripheral blood of patients with LSCC, while MAGE-A expression was not detected in the healthy donors. These are consistent with previous studies (35,36). A total of 18 patients were positive for only one MAGE-A gene, 12 patients were positive for two genes, seven patients were positive for three genes, eight patients were positive for four genes, eight patients were positive for five genes, and two patients were positive for six genes.…”

Section: Discussionsupporting

confidence: 92%

MAGE‑A genes as predictors of the outcome of laryngeal squamous cell carcinoma

Liu

Zhao

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Laryngeal squamous cell carcinoma (LSCC) is one of the most common malignant tumors in the head and neck area. Melanoma-associated antigens A (MAGE-A) are strictly tumor-specific and are expressed in several types of tumors. To date, no studies have reported the potential of MAGE-A genes as markers for circulating tumor cells (CTCs) in patients with LSCC. The present study aimed to evaluate the expression and the possible prognostic significance of MAGE-A in the peripheral blood of patients with LSCC. In the present study, the expression of MAGE-A genes was determined by multiplex semi-nested PCR and restriction endonuclease treatment of the peripheral blood of patients with LSCC. The association between MAGE-A gene expression and clinicopathological parameters and prognosis was evaluated. The results demonstrated that the expression of MAGE-A was associated with the predictors that indicate poor prognosis. The expression levels of MAGE-A and each individual MAGE-A gene were also associated with a shorter overall survival time of patients with LSCC. In conclusion, the results of the present study suggested that the expression of MAGE-A genes may be a potential prognostic marker for patients with LSCC.

show abstract

Section: Discussionsupporting

confidence: 92%

MAGE‑A genes as predictors of the outcome of laryngeal squamous cell carcinoma

Liu

Zhao

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…MAGE is a member of the cancer/testis antigen family. Since it was first isolated and cloned from melanoma in 1991, at least 13 subfamilies and 83 closely related gene members of the MAGE family have been found [ 11 ]. In general, MAGE is mainly manifested in the testicles and placenta, but it is widely and highly expressed in a variety of malignant tumors and has a certain correlation with tumorigenesis, development, drug resistance, and prognosis [ 12 ].…”

Section: Discussionmentioning

confidence: 99%

Analysis of the Clinical Value of MAGE-A9 Expressions in Cervical Cancer Tissues and PBMC

et al. 2022

Emergency Medicine International

View full text Add to dashboard Cite

Objective. The aim of this study is to explore the expressions and clinical significance of melanoma-associated antigen-A9 (MAGE-A9) in cervical cancer tissues and peripheral blood mononuclear cells (PBMC). Methods. 108 patients who were scheduled to undergo cervical conization or extensive hysterectomy between March 2019 and January 2021 due to cervical lesions were selected by convenient sampling. According to postoperative pathological results, the patients were divided into a cervical cancer group (n = 64) and cervical intraepithelial neoplasia (CIN) group (n = 44). The expression levels of MAGE-A9 mRNA in cervical lesion tissues and PBMC were detected by real-time fluorescence quantitative PCR, and the expression of MAGE-A9 protein in lesion tissues was detected by immunohistochemistry. The correlation between MAGE-A9 mRNA expressions in cancer tissues and PBMC and serum tumor markers in patients with cervical cancer and the relationship between MAGE-A9 protein expression in cancer tissues and clinicopathological characteristics were analyzed, and a receiver operating characteristic curve (ROC curve) was drawn to explore the diagnostic value of MAGE-A9 mRNA expressions in cancer tissues and PBMC on cervical cancer. Results. The expression levels of MAGE-A9 mRNA in cervical lesion tissues and PBMC in the cervical cancer group were significantly higher than those in the CIN group ( P < 0.05 ), and the levels of serum SCC-Ag, CA-125, and CEA were significantly higher than those in the CIN group ( P < 0.05 ). The positive rate of the MAGE-A9 protein expression in cervical lesion tissues in the cervical cancer group was significantly higher than that in the CIN group ( P < 0.05 ). The expression levels of MAGE-A9 mRNA in cancer tissues and PBMC of patients with cervical cancer were positively correlated with serum SCC-Ag, CA-125, and CEA ( P < 0.05 ). The positive rate of the MAGE-A9 protein expression in cervical cancer tissues was related to FIGO stage, tumor diameter, degree of differentiation, lymph node metastasis, and high-risk HPV infection ( P < 0.05 ) and was not correlated with age and pathological type ( P > 0.05 ). The areas under the ROC curves of MAGE-A9 mRNA in lesion tissue and MAGE-A9 mRNA in PBMC were 0.925 and 0.900 in the diagnosis of cervical cancer ( P < 0.05 ). Conclusion. The expressions of MAGE-A9 in cancer tissues and PBMC of patients with cervical cancer are upregulated, which is related to the levels of serum tumor markers and the progression of disease. MAGE-A9 is expected to become an important marker for the diagnosis of early cervical cancer.

show abstract

“…However, suppressing MAGEA12 expression decreased the migratory and invasive capacities of both cell lines, notwithstanding the differences between the lines in terms of migration and invasion (Figure 4b,c). In addition, we showed that MAGEA12 silencing reduced breast cancer aggressiveness by using a 3D culture system that can identify aggressive characteristics based on a cell shape classification [32][33][34]. Thus, siRNA-mediated MAGEA12 knockdown not only dramatically reduced the expression of MAGEA12, but it also changed the morphology of the cell clusters from their usual aggressive grape-like phenotype to the less aggressive rounded/mass cluster phenotype (Figure 4d).…”

Section: Effect Of Magea12 Silencing and Overexpression On Breast Cancer Cell Aggressivenessmentioning

confidence: 88%

“…Several MAGE-A family genes are also associated with poor prognosis. Thus, MAGEA3, MAGEA6, and MAGEA4 expression correlates significantly with lymph node metastasis in oral squamous cell carcinoma [33]. In addition, high expression of MAGEA9 is associated with poor survival in non-small-cell lung carcinoma [34] and hepatocellular carcinoma [35].…”

Section: Introductionmentioning

confidence: 92%

Epigenetic Upregulation of MAGE-A Isoforms Promotes Breast Cancer Cell Aggressiveness

Kim

et al. 2021

Cancers

View full text Add to dashboard Cite

After decades-long efforts to diagnose and treat breast cancer, the management strategy that has proved most successful to date is molecular-subtype-specific inhibition of the hormone receptors and HER2 that are expressed by individual cancers. Melanoma-associated antigen (MAGE) proteins comprise >40 highly conserved members that contain the MAGE homology domain. They are often overexpressed in multiple cancers and contribute to cancer progression and metastasis. However, it remains unclear whether the biological activity arising from MAGE gene expression is associated with breast cancer subtypes. In this study, we analyzed the RNA-sequencing (RNA-seq) data of 70 breast cancer cell lines and found that MAGEA12 and MAGEA3 were highly expressed in a subset of these lines. Significantly, MAGEA12 and MAGEA3 expression levels were independent of hormone receptor expression levels but were closely associated with markers of active histone modifications. This indicates that overexpression of these genes is attributable to epigenetic deregulation. RNA-seq of MAGEA12-depleted cells was then used to identify 382 candidate targets of MAGEA12 that were downregulated by MAGEA12 depletion. Furthermore, our gain-of-function experiments showed that MAGEA12 overexpression promoted aggressive behaviors of malignant breast cancer cells, including enhancing their cell migration and invasion. These changes were associated with increased epigenetic deregulation of the MAGEA12 signature genes. Thus, MAGEA12 may play an important role in breast cancer malignancy. Taken together, our findings suggest that MAGEA12 could be a promising therapeutic target in breast cancer, and its overexpression and epigenetic changes could serve as subtype classification biomarkers.

show abstract

The expression of melanoma-associated antigen A (MAGE-A) in oral squamous cell carcinoma: an evaluation of the significance for tumor prognosis

Cited by 6 publications

References 46 publications

MAGE‑A genes as predictors of the outcome of laryngeal squamous cell carcinoma

MAGE‑A genes as predictors of the outcome of laryngeal squamous cell carcinoma

Analysis of the Clinical Value of MAGE-A9 Expressions in Cervical Cancer Tissues and PBMC

Epigenetic Upregulation of MAGE-A Isoforms Promotes Breast Cancer Cell Aggressiveness

Contact Info

Product

Resources

About